Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 4/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716640 | 1.00 | GNAI3 (0.42) | GNAI3GNAO1GNAI1USP2HTT | |
| SCHEMBL4342012 | 0.96 | GNAI3 (0.46) | GNAI3GNAO1GNAI1USP2HTT | |
| SCHEMBL718757 | 0.93 | GNAI3 (0.38) | GNAI3GNAO1GNAI1USP2HTT | |
| SCHEMBL718755 | 0.93 | GNAI3 (0.38) | GNAI3GNAO1GNAI1USP2HTT | |
| SCHEMBL720502 | 0.84 | HTT (0.35) | GNAI3GNAO1GNAI1HTTLMNA | |
| SCHEMBL1477738 | 0.84 | HTT (0.35) | GNAI3GNAO1GNAI1HTTLMNA | |
| SCHEMBL717870 | 0.83 | GNAI3 (0.44) | GNAI3GNAO1GNAI1USP2ACE2 | |
| SCHEMBL718213 | 0.83 | GNAI3 (0.44) | GNAI3GNAO1GNAI1USP2ACE2 | |
| SCHEMBL31215313 | 0.81 | TP53 (0.50) | GNAI3GNAO1GNAI1USP2MMP3 | |
| SCHEMBL717828 | 0.78 | FFAR1 (0.33) | GNAI3GNAO1GNAI1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710943-A2 | TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME | Molecular Transfer, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4565572-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250154525-A1 | PLANT VIRUS MOVEMENT PROTEINS AND METHODS OF USING SAME | MOLECULAR TRANSFER, INC. | 2025-05-15 | — | — | US | claimed |
| WO-2025034802-A2 | AGENTS FOR DELIVERY OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2025-02-13 | — | — | WO | claimed |
| WO-2025034764-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Life Technologies Corporation (US) | 2025-02-13 | — | — | WO | claimed |
| EP-4406963-A2 | TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME | Molecular Transfer, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| US-12037600-B2 | Transfection complexes and methods of using the same | MOLECULAR TRANSFER, INC. (US) | 2024-07-16 | — | — | US | claimed |
| CN-118271422-A | Transfection complexes and methods of use thereof | 分子传递有限公司 | 2024-07-02 | — | — | CN | claimed |
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | claimed |
| EP-3341027-B1 | TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME | MOLECULAR TRANSFER INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-2912045-A2 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2015-09-02 | — | — | EP | claimed |
| WO-2014070687-A2 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2014-05-08 | — | — | WO | claimed |
| EP-2696678-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2013158127-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2013-10-24 | — | — | WO | claimed |
| EP-2015780-B1 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER INC (US) | 2012-12-12 | — | — | EP | claimed |
| WO-2012142622-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2012-10-18 | — | — | WO | claimed |
| US-7915230-B2 | Reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER (US) | 2009-01-22 | — | — | US | claimed |
| EP-2015780-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2009-01-21 | — | — | EP | claimed |
| WO-2007130073-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2007-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154525-A1 | PLANT VIRUS MOVEMENT PROTEINS AND METHODS OF USING SAME | HDLBP, PHAX, PLTP | GNAI3 534/4885GNAO1 2667/4885GNAI1 1161/4885 |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | FUS, PHAX, PICALM | GNAI3 1694/4885GNAO1 3683/4885GNAI1 1884/4885 |
| US-12037600-B2 | Transfection complexes and methods of using the same | TIAL1, NPC1L1, LIPA | GNAI3 1083/4885GNAO1 3364/4885GNAI1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.